hotspot -WSS

hotspot

author：hotspot 2025-09-03 03:26:15 - browse：595

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： STAT Summit: How researchers deal with rejection

WSS

Virtual care provider acquires bankrupt Pear's prescription apps

Results on Novartis prostate cancer therapy could expand its use

STAT Summit: Ending the crisis of Black deaths in the U.S.

Drinking less cuts risk of oral cavity, esophageal cancer: Report

CRISPR gene editing developments we’re watching in 2024

Three trends to watch in biotech in 2024

focus

hotspot

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Heart attack and stroke risk calculators need revising

STAT Summit: Meghan O’Rourke on making chronic illness visible

Peter Hotez and the public health issue of online harassment

In Spain, a hospital brews its own CAR

Sports medicine is finally prioritizing gender equality

FDA clears Verve to begin U.S. study of gene

United colonoscopy coverage change 'may cost lives,' doctors say

Roivant's CEO is a star, but biotech's black hole persists

explore

STAT Summit: How researchers deal with rejection

Why health care costs have stayed mostly flat since 2010

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Medicare Advantage beneficiaries sue Humana over algorithm use

Hospitals owned by private equity see complications spike 25%

entertainment

focus

focus

hotspot